Key result
Maternal aspirin improves survival and blunts neurodevelopmental pathogenesis in CMV-infected rat offspring.
Why the study?
Congenital CMV infections are a leading cause of neurodevelopmental disorders with no satisfactory therapy and unclear pathophysiology involving immune processes in the developing brain.
Does maternal administration of aspirin prevent neurodevelopmental pathogenesis in a rat model of fetal brain CMV infection?
Does maternal administration of aspirin prevent neurodevelopmental pathogenesis in a rat model of fetal brain CMV infection?
p-value: p=0.009
Maternal intake of aspirin during pregnancy improves CMV-related neurodevelopmental alterations in a rat model, providing proof-of-principle for its potential use against congenital CMV infections.
Hypothesis-generating in rat fetal CMV; leaves open human translation and safety in pregnancy.
BACKGROUND: Congenital cytomegalovirus (CMV) infections represent one leading cause of human neurodevelopmental disorders. Despite their high prevalence and severity, no satisfactory therapy is available and pathophysiology remains elusive. The pathogenic involvement of immune processes occurring in infected developing brains has been increasingly documented. Here, we have used our previously validated rat model of CMV infection of the fetal brain in utero to test whether the maternal administration of four different drugs with immunomodulatory properties would have an impact on the detrimental postnatal outcome of CMV infection. METHODS: CMV infection of the rat fetal brain was done intracerebroventricularly. Each of the drugs, including acetylsalicylic acid (aspirin, ASA), a classical inhibitor of cyclooxygenases Cox-1 and Cox-2, the two key rate-limiting enzymes of the arachidonic acid-to-prostaglandins (PG) synthesis pathway, was administered to pregnant dams until delivery. ASA was selected for subsequent analyses based on the improvement in postnatal survival. A combination of qRT-PCR, mass spectrometry-based targeted lipidomics, immunohistochemistry experiments, monitoring of neurologic phenotypes and electrophysiological recordings was used to assess the impact of ASA in CMV-infected samples and pups. The postnatal consequences of CMV infection were also analyzed in rats knocked-out (KO) for Cox-1. RESULTS: microglia unchanged. Maternal intake of ASA also improved the key postnatal in vivo phenotypes caused by CMV infection and dramatically prevented against the spontaneous epileptiform activity recorded in neocortical slices from CMV-infected pups. In contrast with maternal intake of ASA, Cox-1 KO pups displayed no improvement in the in vivo phenotypes after CMV infection. However, as with ASA administration, the spontaneous epileptiform activity was dramatically inhibited in neocortical slices from CMV-infected, Cox-1 KO pups. CONCLUSION: Overall, our data indicate that, in the context of CMV infection of the fetal brain, maternal intake of ASA during pregnancy improved CMV-related neurodevelopmental alterations in the offspring, likely via both Cox-1 dependent and Cox-1 independent mechanisms, and provide proof-of-principle for the use of ASA against the detrimental outcomes of congenital CMV infections.
No takes yet. Share an insight, caveat, or question.
Tarhini et al. (2024) studied Congenital cytomegalovirus (CMV) infection. Acetylsalicylic acid (aspirin) vs. Untreated CMV infection was evaluated on Postnatal survival (p=0.009). Maternal intake of aspirin during pregnancy significantly improved postnatal survival (p=0.009) and blunted neurodevelopmental pathogenesis in rat offspring with fetal cytomegalovirus infection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: